Atopic Dermatitis kucheneswa kweganda nekurapa kutsva

Vanopfuura 50 muzana yevarwere vane pakati-kusvika-yakanyanya atopic dermatitis (AD) vakawana zvishoma makumi manomwe neshanu muzana mukuderedzwa kwechirwere (EASI-75*) pamasvondo gumi nematanhatu pavakagamuchira lebrikizumab monotherapy muchirongwa cheAdvocate, Almirall SA (BME: ALM ) yakaziviswa nhasi kuAmerican Academy yeDermatology (AAD) Musangano Wepagore. Lebrikizumab, yekuferefeta IL-75 inhibitor, zvakare yakatungamira kune kiriniki inonzwisisika kuvandudzwa kwe itch uye zvimwe zvakakosha zvakashumwa nemurwere zvichienzaniswa ne placebo.              

"Zviratidzo zveatopic dermatitis senge itch, ganda rakaoma, kurwadziwa kwakanyanya uye kuzvimba zvinoremedza hupenyu hwevarwere pamwe nekurarama kwavo. Varwere vanotsvaga mishonga inopa inoshanda uye inotenderwa nzira dzekurapa dzinogona kugadzirisa izvo zviratidzo nekuvandudza hupenyu hwavo. Lebrikizumab inyanzvi yekurapa ine chaiyo inhibition yeIL-13, iyo yepakati pathogenic murevereri muAD. Kuonekwa kwekuita kwe lebrikizumab mune zvidzidzo izvi kunosimbisa kukwanisa kweiyi itsva kurapwa, iyo inogona kunge yakagamuchirwa zvakanaka kune atopic dermatitis armamentarium, "akadaro Prof. Dr. med. Diamant Thaçi, Director paComprehensive Center for Inflammation Medicine paYunivhesiti yeLübeck kuGermany, uye mukuru anoongorora kutongwa kweAdvocate 2.

Lebrikizumab is monoclonal antibody (mAb) inosungira kune interleukin 13 (IL-13) protein ine high affinity kudzivirira zvakananga kuumbwa kweIL-13Rα1 / IL-4Rα (Type 2 receptor) iyo inovhara pasi pasi pasi kuburikidza neIL-13. nzira. 1-5 IL-13 inobata basa repakati muRudzi rwechipiri kuzvimba.2 Muna AD, IL-6 inodzika zviratidzo nezviratidzo zvinosanganisira kusashanda kweganda barriers, itch, utachiona uye nzvimbo dzakaoma, dzakakora dzeganda.13

MuAdvocate 1, 43 muzana yevarwere vanowana lebrikizumab vakawana ganda rakajeka kana rakajeka (IGA) pamavhiki gumi nematanhatu zvichienzaniswa negumi nematanhatu muzana yevarwere vanotora placebo. Pakati peavo vanogamuchira lebrikizumab, 16 muzana vakawana EASI-13 mhinduro, zvichienzaniswa ne59 muzana ine placebo.

MuAdvocate 2, 33 muzana yevarwere vanotora lebrikizumab vakawana ganda rakajeka kana rakajeka (IGA) pamavhiki gumi nematanhatu, zvichienzaniswa negumi neimwe muzana yevarwere vari pa placebo. Pakati peavo vanogamuchira lebrikizumab, 16 muzana vakawana mhinduro yeEASI-11, zvichienzaniswa ne51 muzana inotora placebo.

Mukati memavhiki mana, varwere vaigamuchira lebrikizumab vakawana kuvandudzwa kwakakosha mukucheneswa kweganda uye kurumwa, pamwe nekuvandudzwa kwekuvhiringidzwa kwekurara pakurara, uye hupenyu hwehupenyu, sekuyerwa neakakosha echipiri magumo.

Nhoroondo yekuchengetedza ye16-vhiki yenguva yaienderana neyekutanga lebrikizumab zvidzidzo muAD. Varwere vanotora lebrikizumab, vachienzaniswa ne placebo, vakarondedzera kuderera kwezviitiko zvakashata muADvocate 1 (lebrikizumab: 45%, placebo: 52%) uye Advocate 2 (lebrikizumab: 53%, placebo: 66%). Zviitiko zvakawanda zvakashata muzvidzidzo zviviri izvi zvaive zvinyoro kana zvine mwero mukuomarara uye zvisina musoro uye hazvina kutungamira mukuregedzwa kwekurapa. Zviitiko zvakajairika zvakanyanya muAdvocate 1 uye 2 kune avo vari pa lebrikizumab vaive conjunctivitis (7% uye 8%, zvichiteerana), inotonhora (nasopharyngitis) (4% uye 5%, zvichiteerana) uye musoro (3% uye 5%, zvichiteerana. )

“Data idzva rakanaka kubva muchikamu chechitatu chezvidzidzo zveAdvocate 3 neAdvocate 1 zvakaratidzwa kuAmerican Academy of Dermatology Annual Meeting zvinoratidza kuti lebrikizumab ine mukana wekuve mushonga unotungamira kuchizvarwa chitsva chebiologics. Varwere vanoda nzira itsva dzekurapa dzinopa kushanda kwepamusoro uye kushivirira kuri nani. Ichi chiitiko chakakosha chinoita kuti tirambe takaisa pfungwa dzedu pane chimwe chezvigadzirwa zvakakosha mupombi yedu yenguva yekupedzisira uye kufambisira mberi kuzvipira kwedu mukusimudzira hupenyu hwevarwere kuburikidza nekurapa kwazvino, "akadaro Karl Ziegelbauer, Ph.D. Almirall SA's Chief Scientific Officer.

Tsanangudzo yemavhiki makumi mashanu nembiri kubva kuAdvocate 52 ne1, pamwe nedata remavhiki gumi nematanhatu kubva kuADhere, Chidzidzo chechitatu AD chelebrikizumab ine topical steroids, chichaburitswa mumwedzi iri kuuya. Almirall naEli Lilly neKambani vanoronga kuendesa mafaera kune zviremera zvepasirese pakupera kwa2 zvichitevera kupera kwezvidzidzo zveAdvocate.

"Tinotarisira kugovera mhinduro dzenguva refu kubva kuAdvocate 1 uye 2 gore rino, izvo zvatinotenda zvichasimbisa kuti lebrikizumab inogona kupa zororo rinodiwa kune vanhu vanonetsekana nechirwere ichi chisingaperi, uye kazhinji, chirwere chehupenyu hwese," akadaro Lotus. Mallbris, MD, Ph.D., mutevedzeri wemutungamiri weglobal immunology development and medical affairs kuLilly.

Almirall yakapa mvumo yekugadzira nekutengesa lebrikizumab yekurapa kwedermatology zviratidzo, kusanganisira AD, muEurope. Lilly ane kodzero dzakakwana dzekusimudzira uye kutengeserana kwelebrikizumab muUnited States nepasirese kunze kweEurope.